GILEAD SCIENCES, INC. (GILD) Share buybacks
- Total buybacks · last 12 months (USD): Value $1.44B; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2026-06-30..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2026-06-30..
Share buybacks
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $1.44B | Trailing-year cash paid for share repurchases. Period ending 2026-06-30. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 1.44B USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2026-06-30 | $1.44B | (m) | (m) |
| 2026-03-31 | $1.61B | (m) | (m) |
| 2025-12-31 | $1.92B | (m) | (m) |
| 2025-09-30 | $2.04B | (m) | (m) |
| 2025-06-30 | $1.91B | (m) | (m) |
| 2025-03-31 | $1.48B | (m) | (m) |
| 2024-12-31 | $1.15B | (m) | (m) |
| 2024-09-30 | $950.00M | (m) | (m) |
| 2024-06-30 | $950.00M | (m) | (m) |
| 2024-03-31 | $1.00B | (m) | (m) |
| 2023-12-31 | $1.00B | (m) | (m) |
| 2023-09-30 | $1.64B | (m) | (m) |
| 2023-06-30 | $1.52B | (m) | (m) |
| 2023-03-31 | $1.44B | (m) | (m) |
| 2022-12-31 | $1.40B | (m) | (m) |
| 2022-09-30 | $653.00M | (m) | (m) |
| 2022-06-30 | $618.00M | (m) | (m) |
| 2022-03-31 | $589.00M | (m) | (m) |
| 2021-12-31 | $546.00M | (m) | (m) |
| 2021-09-30 | $497.00M | (m) | (m) |
| 2021-06-30 | $553.00M | (m) | (m) |
| 2021-03-31 | $564.00M | (m) | (m) |
| 2020-12-31 | $1.58B | (m) | (m) |
| 2020-09-30 | $1.69B | (m) | (m) |
| 2020-06-30 | $1.71B | (m) | (m) |
| 2020-03-31 | $2.24B | (m) | (m) |
| 2019-12-31 | $1.75B | (m) | (m) |
| 2019-09-30 | $2.61B | (m) | (m) |
| 2019-06-30 | $2.83B | (m) | (m) |
| 2019-03-31 | $2.69B | (m) | (m) |
| 2018-12-31 | $2.90B | (m) | (m) |
| 2018-09-30 | $2.04B | (m) | (m) |
| 2018-06-30 | $1.75B | (m) | (m) |
| 2018-03-31 | $1.43B | (m) | (m) |
| 2017-12-31 | $954.00M | (m) | (m) |
| 2017-09-30 | $1.85B | (m) | (m) |
| 2017-06-30 | $2.69B | (m) | (m) |
| 2017-03-31 | $3.57B | (m) | (m) |
| 2016-12-31 | $11.00B | (m) | (m) |
| 2016-09-30 | $13.05B | (m) | (m) |
| 2016-06-30 | $15.10B | (m) | (m) |
| 2016-03-31 | $15.00B | (m) | (m) |
| 2015-12-31 | $10.00B | (m) | (m) |
| 2015-09-30 | $8.95B | (m) | (m) |
| 2015-06-30 | $7.60B | (m) | (m) |
| 2015-03-31 | $7.90B | (m) | (m) |
| 2014-12-31 | $5.35B | (m) | (m) |
| 2014-09-30 | $3.75B | (m) | (m) |
| 2014-06-30 | $2.15B | (m) | (m) |
| 2014-03-31 | $950.21M | (m) | (m) |
| 2013-12-31 | $582.36M | (m) | (m) |
| 2013-09-30 | $382.30M | (m) | (m) |
| 2013-06-30 | $487.49M | (m) | (m) |
| 2013-03-31 | $728.51M | (m) | (m) |
| 2012-12-31 | $667.04M | (m) | (m) |
| 2012-09-30 | $693.30M | (m) | (m) |
| 2012-06-30 | $1.37B | (m) | (m) |
| 2012-03-31 | $1.86B | (m) | (m) |
| 2011-12-31 | $2.38B | (m) | (m) |
| 2011-09-30 | $2.77B | (m) | (m) |
| 2011-06-30 | $3.44B | (m) | (m) |
| 2011-03-31 | $4.41B | (m) | (m) |
| 2010-12-31 | $4.02B | (m) | (m) |
| 2010-09-30 | $3.65B | (m) | (m) |
| 2010-07-31 | (m) | (m) | (m) |
| 2010-06-30 | $2.38B | (m) | (m) |
| 2010-03-31 | $930.95M | (m) | (m) |
| 2009-12-31 | $998.50M | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) |
| 2008-12-31 | $1.97B | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) |
| 2007-12-31 | $487.54M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |